Αρχική World News Adolescent and Young Adult Cancer Survivors Face More Co-morbidity in Later Life...

Adolescent and Young Adult Cancer Survivors Face More Co-morbidity in Later Life Than Counterparts in the General Population

The risk of developing chronic comorbidities was 2- to 3-fold higher in adolescents and young adults (AYAs) who were successfully treated for cancer, as compared with the general population across nearly all outcomes examined in a large retrospective study appearing in the September 2020 edition of the Journal of Clinical Oncology.  

Lead author Chun Chao, PhD, research scientist at the Kaiser Permanente Southern California and Assistant Professor, Department of Epidemiology, UCLA in Los Angeles, USA and colleagues underscored two key components of AYA cancer survivors: There is now a population of approximately 633,000 AYA cancer survivors in the United States that will continue to grow, and data regarding the risk of chronic comorbidities among AYAs are sparse compared to that compiled for survivors of childhood cancer.

Importantly, the study described the incidence, and relative risk for developing chronic comorbidities in survivors to facilitate development of personalised survivorship care plans for AYA cancer survivors.

The cohorts were well-balanced as to racial, ethnic, and socioeconomic factors

The large retrospective study identified 6,778 survivors of AYA cancer and 87,737 persons with no history of cancer recorded in the Kaiser Permanente Southern California database. This institution provides comprehensive health services to 4.4 million racially, ethnically, and socioeconomically diverse individuals who are representative of the general population.

The AYA cancer cohort comprised individuals diagnosed with invasive cancer between the ages of 15 to 39 years from 2000 to 2012 who survived ≥2 years after cancer diagnosis. The reference cohort included individuals with no cancer history who were matched 13:1 per age, sex and calendar year. Both cohorts were followed for the diagnosis of chronic comorbidity using electronic medical records through 31st December 2014.

The median age of survivors at cancer diagnosis was 31 years; 8% (15 to 19), 25% (20 to 29), and 67% (30 to 39). Approximately 65% of survivors were female, and 42% were non-Hispanic White. The most common cancer diagnoses included breast cancer (16%), thyroid cancer (16%), lymphoma (11%), and melanoma (10%).

Twenty-three percent of survivors were treated with external-beam radiation therapy. Exposure to selected chemotherapy agents ranged from 3% with epipodophyllotoxins to 24% with anthracyclines.

AYA cancer survivors had a 2- to 3-fold increased risk compared to the general population for cardiomyopathy, stroke, premature ovarian failure, chronic liver disease, and renal failure

With median follow-up post cancer diagnosis of 5.1 years, 1,443 (17%) survivors developed ≥1 comorbidity. By Poisson regression the researchers found a significantly higher incidence rate ratio (IRR) for survivors for nearly all comorbidities investigated. The adjusted IRR of developing any comorbidity among survivors of compared with the reference cohort was 1.47 (95% confidence interval [CI] 1.39-1.55). 

The IRR was highest for avascular necrosis (IRR 8.25), followed by osteoporosis (IRR 5.75), joint replacement (IRR 3.89), stroke (IRR 3.19), premature ovarian failure (IRR 2.87), and cardiomyopathy or heart failure (IRR 2.64).

The adjusted IRR of developing ≥2 incident comorbidities was 1.63 (95% CI 1.48-1.78). At 10 years after the index date the prevalence of multiple comorbidities in survivors approached 49% versus 20% in the reference population (p < 0.001).

The most common co-morbidities among AYA survivors included dyslipidemia hypertension, diabetes, thyroid disorders, and severe depression or anxiety.

Chemotherapy and radiation therapy significantly associated with specific co-morbidities

Significant associations by multivariable analyses were found between exposure to cancer treatments versus no exposure and the development of co-morbidities. Cardiomyopathy associated with alkylating agent treatment at >2,500 mg/m2 (IRR 2.8), anthracycline at >240 mg/m2 (IRR 3.3), and trastuzumab at >4,000 mg/m2 (IRR 8.1) as well as chest radiation ≥30 Gy (IRR 2.6). Pulmonary fibrosis was significantly associated with bleomycin >120 mg/m2 therapy (IRR 4.7).

Avascular necrosis associated with any dose level of methotrexate (IRR 21.6) or corticosteroids (IRR 5.4), and any dose of corticosteroids significantly associated with osteoporosis (IRR 2.3).

Premature ovarian failure associated with the use of alkylating agents at >2,500 mg/m2 (IRR 4.5) or platinum agents >450 mg/m2 (IRR 9.0).

Hearing loss significantly associated with combined exposure to platinum at >450 mg/m2 and radiation ≥30 Gy to the head (IRR 14.9). Radiation therapy ≥30 Gy to the head and/or neck also was associated with the risk of stroke (IRR 3.5), thyroid disorders (IRR 3.1), and diabetes (IRR 1.9).


This study highlights the increased risk of developing comorbidities in AYA survivors of cancer compared with the general population and correlates the exposure to cancer treatment with the risk of developing specific comorbidities. The data have important implications for survivorship care planning. The findings facilitate the identification of high-risk survivors who may benefit from tailored surveillance and prevention strategies.

These findings underscore the need for age-appropriate survivorship guidelines for survivors of AYA cancer and set the stage for prevention, early diagnosis, and intervention strategies to mitigate the long-term comorbidity burden in the growing population of long-term survivors.

No external funding was disclosed.


Chao C, Bhatia S, Xu L, et al. Chronic Comorbidities Among Survivors of Adolescent and Young Adult Cancer. Journal of Clinical Oncology 2020;38(27):3161-3174. DOI: 10.1200/JCO.20.00722.



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

De qué manera el seguimiento de los síntomas mejora la atención oncológica

Se sabe bien que el tratamiento contra el cáncer genera efectos secundarios significativos. Por ejemplo, la quimioterapia puede causar caída del cabello, náuseas e...

Apalutamide Plus ADT Provides Significant Improvement in Overal Survival and Delays Onset of Progression in mCSPC

The final analysis of the TITAN demonstrates that the long-term use of apalutamide plus androgen deprivation therapy (ADT) provided significant improvement in overall survival...

Man Who Lost His Mother to Breast Cancer Opens Resource Center in Her Memory

After the death of a beloved parent, you can find yourself wanting to carry their legacy forward in their absence. One man in Ohio...

Navigating Cancer Survivorship as a Transgender or Non-Binary Person

Mal Malme (Mal or they/them) is a proud Boston-based theater artist, activist, writer, and health care clown. Mal is co-founder of Queer Soup Theater...

Sing Anyway

“Some days there won’t be a song in your heart. Sing anyway.” – Emory Austin I love this thought from Emory Austin. I am reminded...

Topotecan–Berzosertib Combination Shows Promise against Small Cell Lung Cancer

May 5, 2021, by NCI Staff A small clinical trial tested the combination of topotecan with the drug berzosertib, which inhibits a protein that helps repair...